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Abstract
Background: The proportion of patients with controlled hypertension (< 140/90 mmHg) is very low in India. Thus,
there is a need to improve blood pressure management among patients with uncontrolled hypertension through
innovative strategies directed at health system strengthening.
Methods: We designed an intervention consisting of two important components – an electronic decision support
system (EDSS) used by a trained nurse care coordinator (NCC). Based on preliminary data, we hypothesized that this
intervention will be able to reduce mean systolic blood pressure by 6.5 mmHg among those with uncontrolled blood
pressure in the intervention arm compared to the standard treatment arm (paper-based hypertension treatment
guidelines). The study will adopt a cluster randomized trial design with the community health center (CHC) as the unit of
randomization. The trial will be conducted in Visakhapatnam district (southern India). A total of 1876 participants aged
≥30 years with high blood pressure – systolic blood pressure (SBP)≥ 160 mmHg or diastolic blood pressure (DBP)≥
90 mmHg will be enrolled from 12 CHCs. The intervention consists of trained NCCs equipped with an evidence-based
hypertension treatment algorithm in the form of the EDSS with regular SMSs to patients with hypertension to promote
hypertension treatment and blood pressure control for 12 months. The primary outcome will be difference in the mean
change of SBP, from baseline to 12 months, between the intervention and the standard treatment arm. The secondary
outcomes are the difference in mean change of DBP; difference in the proportion of patients with controlled blood
pressure (< 140/90 mmHg); difference in mean change of fasting blood sugar, HbA1C, eGFR, and albumin to creatinine
ratio; difference in the proportion of patients visiting the CHC regularly (number of actual visits to the CHC/number of
visits suggested by the EDSS > 80%); difference in proportion of patients compliant to anti-hypertensive medication/s;
cost-effectiveness of intervention versus enhanced care. All the outcomes will be assessed at 12 months.
Discussion: The study is expected to provide evidence on the effectiveness of NCC-led, EDSS-based hypertension
management in India and can likely offer an exemplar for improving cardiovascular disease (CVD) management in
India within the resource-constrained public healthcare system.
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Background
Non-communicable diseases (NCDs) are the number-one
cause of death in India [1]. Cardiovascular diseases (CVDs)
cause the majority of deaths among NCDs. High blood
pressure or hypertension is one of the important risk factors
for CVD. The prevalence of hypertension is rising steadily
– both in urban as well as rural India. Estimates suggest
that out of 10 patients with hypertension only one has their
blood pressure meeting recommended targets [2]. Thus,
there exists a huge need and potential to improve manage-
ment among those with uncontrolled blood pressure.
The public healthcare system in India is overburdened,
and has yet to reorient fully to address NCDs. The busy
out-patient settings of the public healthcare facilities offer
little time for the physicians to provide optimal treatment
and care for patients with hypertension, who need a steady
medication supply as well as intensive teaching on diet
and medication compliance. Task-shifting/sharing, a
process wherein certain tasks can be delegated to less
qualified but appropriately trained paramedical workers,
like nurses [3], offers a potential solution to improve the
sub-optimal management of hypertension. mHealth, i.e.,
the use of mobile and wireless technologies to support the
achievement of health objective [4] technology has shown
promising results with improvement in medication adher-
ence for NCD treatment [5], physical activity and promo-
tion of healthy diets among patients with NCDs [6]. Thus,
mHealth can be leveraged to equip the nurses with the
tools to assist the physicians in managing blood pressure.
Our pilot study, with a pre-post design, implemented in
northern India, has previously shown that this model can
achieve substantial reductions in blood pressure and blood
sugar [7]. The intervention consisted of task-sharing with an
electronic decision support system (EDSS) to aid physicians
in the management of blood pressure of patients with un-
controlled hypertension. The reductions in systolic blood
pressure (SBP) and diastolic blood pressure (DBP) at the
end of 18 months were 14.6 mmHg and 7.6 mmHg, respect-
ively. However, this pilot study lacked a comparator group.
In order to rigorously test the feasibility and effectiveness of
this intervention, i.e., a trained NCC who uses an EDSS to
guide blood pressure treatment in a public healthcare set-
ting, we plan to conduct a cluster randomized control trial
involving patients visiting the community health centers
(CHCs) of the southern Indian state of Andhra Pradesh.
Methods
Trial design
The study will be a parallel-group, cluster randomized trial
to test the effectiveness of a trained NCC-led intervention
by comparing with usual care. The trial design schema is
depicted in Fig. 1. The corresponding Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
2013 Checklist [8] is provided as Additional file 1.
Trial site selection
The study will be carried out in the CHCs of Visakhapat-
nam district which has a population of approximately
4,000,000. The district has three distinct geographical divi-
sions – urban, rural and tribal. Nearly 46% of the total
population live in the city of Visakhapatnam. A CHC is a
secondary-level public healthcare facility providing referral
services and caters to a population of 80,000 to 120,000.
As per the Indian Public Health Standards (IPHS) [9], a
CHC has to provide specialty services (general medicine,
general surgery, pediatrics, obstetrics and gynecology, and
anesthesia) and is headed by a block medical officer or a
medical superintendent. The list of all the CHCs in Visa-
khapatnam district was obtained from the office of the
District Coordinator of Hospital Services (DCHS), Visa-
khapatnam. A total of 13 CHCs are functioning in Visa-
khapatnam district. In one CHC, a comprehensive
diabetes and hypertension prevention and management
program, titled UDAY, is already being implemented. We
obtained permission from the DCHS to implement the
m-Power Heart Project in the remaining 12 CHCs.
Eligibility criteria
All 12 CHCs will be eligible for participating in the
study. The participant inclusion and exclusion criteria
are listed in Table 1.
Intervention
The intervention has two important components. The first
is the EDSS which has been developed as an android appli-
cation installed in a tablet. The EDSS uses an algorithm de-
veloped by national and international experts, based on
national and international guidelines [10–13] for the man-
agement of hypertension. The EDSS considers a patient’s
current age, blood pressure level, any co-morbid conditions
and current medication (type, dose, and frequency) to
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suggest to the physician the best course of treatment. For
example, consider that a male patient aged 58 years, taking
amlodipine (5 mg once daily), has a SBP of 160 mmHg and
a diastolic blood pressure (DBP) of 90 mmHg and no other
co-morbidities. The EDSS recommends to the physician
to add enalapril 5 mg or losartan 50 mg once daily. The
EDSS also screens patients for chronic kidney disease
(CKD) by calculating the estimated glomerular filtration
rate (eGFR) based on current serum creatinine value [14]
and alerting the physician to refer high-risk patients (e.g.,
Fig. 1 Schema of the m-Power Heart Project. Footnote: EDSS – electronic decision support system
Table 1 Inclusion and exclusion criteria of study participants
Inclusion criteria 1. Age ≥ 30 years
2. On treatment for hypertension or opportunistically screened and diagnosed with hypertension, with a blood pressure
of ≥160/90 mmHg
3. With or without co-morbidities (diabetes mellitus, left ventricular hypertrophy, chronic kidney disease, heart failure,
coronary artery disease, and peripheral vascular disease)
Exclusion criteria 1. Pregnant women
2. Unwilling/unable to provide written informed consent for the study
3. Diagnosed with a malignancy or life-threatening condition
4. Currently enrolled in other trials
5. Plans to move residence in the year ahead
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eGFR < 30 ml/min/1.73 m2) to a higher level of care (i.e.,
district hospital in Visakhapatnam) where the services of a
nephrologist are available for the management of CKD.
Apart from the clinical recommendation, the EDSS also
recommends lifestyle changes (reduction of salt, increase
in consumption of fruits and vegetables, quitting tobacco
and alcohol). The EDSS will facilitate patient data man-
agement by storing the information electronically (which
is currently not available in the CHCs) and also provide a
structured follow-up plan for each patient.
The second important component of the intervention is
the NCC-led care. The task of management of hyperten-
sion is shared with the physician by the NCC. The NCC
will measure blood pressure, provide counseling on lifestyle
changes, facilitate treatment and follow-up and promote
adherence to the prescribed treatment and follow-up
schedule. The NCCs will receive training in the diagnosis
and management of hypertension and its co-morbidities,
and in the use of EDSS. The NCC will be supported by an
automated short messaging service (SMS) that will regu-
larly send messages in the local language to patients en-
rolled in the study. The SMS will convey information on
various aspects of hypertension and its management – risk
factors, importance of lifestyle changes, regular intake of
medication, reminders on follow-up visits, etc. A bank of
approximately 50 messages will be developed in English in
consultation with study investigators and experts in the
field of hypertension management and translated into the
local language for transmission to the patients.
Usual care
In the standard treatment arm CHC, the regular and
routine care will continue. The physicians will be pro-
vided with paper-based current evidence-based manage-
ment guidelines. The physicians in both the arms will
receive refresher training on hypertension management
prior to the randomization of CHCs.
Outcomes
Primary outcome
Difference in the mean change of SBP, from baseline to
12 months, between the intervention and enhanced
care arms
Secondary outcome(s)
i Difference in the mean change from baseline to
12 months between the intervention and enhanced care
arms in:
◦ DBP
◦ Fasting blood sugar
◦ Glycated hemoglobin (HbA1C)
◦ Blood urea and serum creatinine
◦ eGFR and albumin to creatinine ratio
ii Difference in the proportion of patients from baseline
to 12 months between the intervention and enhanced
care arms in:
◦ Controlled blood pressure (< 140/90 mmHg)
◦ Albuminuria (urine albumin to creatinine ratio >
30 mg/g)
◦ Visiting the CHC regularly (number of actual visits to
the CHC/number of visits suggested by the EDSS > 80%)
◦ Compliance to anti-hypertensive medication/s
iii Cost-effectiveness of the intervention compared to
standard treatment
All outcomes will be assessed at the end of the inter-
vention, i.e., 12 months.
Participant timeline
The participant timeline is provided in Fig. 2.
Sample size
The sample size has been calculated based on the fol-
lowing – significance at 5%, power of 80%, mean differ-
ence in SBP of 6.5 mmHg between the intervention and
standard treatment arms, standard deviation (SD) of SBP
of 17, intracluster coefficient of 0.03 (estimated from the
baseline study of a comprehensive diabetes and hyper-
tension prevention and management program entitled
UDAY in Visakhapatnam) and attrition rate of 20%. The
sample size will be 936 participants from six CHCs in
each arm, which totals to 1872 from 12 CHCs.
Randomization and blinding
Randomization will be at the level of the CHC in a ratio of
1:1 and will be carried out by a statistician based at the
Public Health Foundation of India (PHFI) in Gurgaon,
India. The randomization will be done only after the base-
line assessment of the eligible participants and the com-
pletion of refresher training of all the physicians in the
CHC in order to maintain the balance between the two
arms prior to the intervention roll out. CHCs will be
assigned to either the intervention or the standard
treatment arm by the statistician. Participants will be en-
rolled by the NCC posted at CHCs. The blinding of either
the study participants or the NCC is not possible. The
imbalance for the baseline covariates leads to poor in-
ternal validity and reduced study power/precision of esti-
mates. The design is based on adjustment of baseline
covariates to avoid chance imbalance. Covariate-constrained
randomization [15, 16] is the method which is used to bal-
ance for many covariates between the intervention and
standard treatment arms. This method limits the risk of se-
lection bias. In this study we propose to balance both arms
by baseline cluster-level covariates; i.e., the proportion of
women, education level, proportion of newly detected
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cases of hypertension and proportion of CKD cases.
The STATA program (cvcrand) will be used to imple-
ment covariate-constrained randomization.
Recruitment
Patients with known hypertension attending the
out-patient clinics will be approached and the study ob-
jectives will be explained to them. If they meet the eligi-
bility criteria, they will be asked to provide their consent
to participate. If they provide consent, baseline question-
naire administration, anthropometry, and bio-sample
collection will be carried out. Apart from patients with
known hypertension, all other patients aged ≥ 30 years
visiting the out-patient clinic for complaints other than
hypertension will be screened via blood pressure meas-
urement and recruited as mentioned above. Recruitment
of the participants will be prior to randomization. To
achieve the target recruitment numbers, co-operation of
the medical superintendent, physicians, and the adminis-
trative staff of CHC will be sought. They will be oriented
to the procedures of recruitment and the trial. Informa-
tion about the trial and the location of NCCs will be dis-
played at the registration counter, out-patient chambers
and other prominent areas of the CHCs to help patients
navigate and find the NCC chamber.
Data collection and management
Baseline and endline assessment of study participants
will be conducted. Data on key sociodemographic vari-
ables (age, sex, education, employment, and household
income), duration of, and treatment for, hypertension,
and lifestyle (diet, physical activity, tobacco and alcohol)
Fig. 2 Schedule of enrollment, assessments, and intervention
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behaviors will be collected electronically. Blood and
urine samples will be collected and analyzed for key
cardio-metabolic parameters (fasting blood sugar,
HbA1C, blood lipids, blood urea, serum creatinine, urine
albumin to creatinine ratio). Blood pressure, height and
weight will be measured. The NCCs will be trained to
administer the questionnaire and carry out the measure-
ments. A trained phlebotomist will be employed for
blood sample collection. All samples collected will be
analyzed in an accredited local laboratory based on
standard laboratory procedures.
The data collected will be stored in the electronic ser-
ver placed at PHFI in Gurgaon, India. The server is
maintained by a dedicated team with regular backup
procedures in place. The access to the information in
the server will be restricted and made available only to
the researchers associated with the m-Power Heart Pro-
ject. Personal identifiers will be removed prior to ana-
lysis. Instead, participant identification numbers will be
used which is not meaningful to casual observers with-
out access to the original study logs (accessible only to
the permitted research team). All data files will be main-
tained under password protection at all times. The study
records will be available to the Institutional Ethics Com-
mittee (IEC).
During the baseline and endline assessments, data will
be monitored daily by the project manager. At the end
of each day, a data dump will be taken from the server
and checked for missing values, errors, and inconsisten-
cies. If found, the information will be passed on to the
concerned NCC and they will be asked to correct the in-
formation prior to carrying out the next interview.
Ischemic heart disease, stroke, end-stage renal disease
(ESRD) or death will be treated as serious adverse events
and recorded by the NCC during each visit to the CHC.
Information on the death of the participants will be col-
lected from the contacts (relatives/friends listed by the
participant during the baseline assessment).
Statistical analysis
The continuous outcome measured at baseline and end
of follow-up (SBP) will be analyzed using individual-level
data with a linear mixed-effects model where the
dependent variable will be the difference in outcome
(after-before) and the main explanatory variable will be
the treatment group. The model will include a random
effect of the CHC to account for the clustered design.
The model will be adjusted by baseline outcome values
in two ways: Firstly, the subject’s “regression to mean ef-
fect” will be controlled by including distance to the CHC
mean of the subject’s baseline outcome value. Secondly,
we will also include the CHC’s baseline outcome mean
to adjust for the baseline differences between CHCs.
The outcome measurements (baseline and final) will be
suitably transformed to achieve normality and to deal
with outliers depending on their distribution, and they
will be centered on the mean of the baseline measure in
each trial arm separately. Such a model will effectively
test if the mean changes in the outcome variable during
the study period are different between the two study
arms while considering the cluster design and the poten-
tial regression to the mean effect. Estimations of the pa-
rameters will be reported along with the 95% confidence
intervals and p values for the null value.
The covariate-constrained randomization will be used
to balance between the intervention and control clusters.
If there is imbalance between the intervention and
standard treatment arms, then the analysis will be ad-
justed for these variables. There is no statistical test for
confounding to decide which variables should enter the
model, so judgment will have to be made based on the
actual imbalances between arms and the association of
those variables with the outcomes. There will be full
transparency and the final results will be presented for
the models unadjusted and adjusted by the baseline vari-
ables that are considered important due to their imbal-
ances between arms. In addition to that, all cluster-level
covariates used in the constrained randomization pro-
cedure will be adjusted in the analysis.
The primary analyses will be conducted under the
principle of intention-to-treat. All randomized patients
will be analyzed in the groups to which they were origin-
ally allocated, regardless of whether they retained that
specific group membership over the course of the trial
or not. Patients who withdrew consent for use of their
data will not be included in any analyses.
Dropouts and lost-to-follow-up are a concern in any
trial. We will compare the baseline characteristics be-
tween those who drop out and those who stay in the
trial. It is very difficult to decide the best way to deal
with this issue a priori before we can verify the extent of
the problem in the final dataset. In general, the approach
for each outcome will be to perform and present both:
complete case analysis and multiple imputation analysis
and, if there are substantial differences in the results, we
will discuss which one seems more reasonable given the
characteristics of the missing data. We will also consider
other subgroup analyses based on other variables such
as co-morbid diabetes, co-morbid CKD and new versus
prior diagnosis of hypertension. The findings will be re-
ported according to the Consolidated Standards of
Reporting Trial (CONSORT) guidelines [17].
Process evaluation
The Consolidated Framework For Implementation Re-
search (CFIR) [18] will be used to evaluate the process
of implementation of the trial. The aim of the process
evaluation is to understand the contextual factors under
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which the intervention was implemented, the reasons
behind the success/failure of the intervention and the
challenges faced by the NCCs in implementation of the
intervention. The results of the process evaluation will
contribute to better understanding of the process and
aid in potential scale-up of the intervention to other
similar settings.
The process evaluation will employ qualitative
methods. Focus group discussions (FGDs) with the pa-
tients visiting the CHCs, key informant interviews with
the physicians and superintendents of the CHCs and
in-depth interviews with NCCs will be conducted. All
interviews and discussion will be audio-recorded after
obtaining the requisite permission from the respective
participants. The recordings will be transcribed and
translated as soon as possible. Descriptive content ana-
lysis will be carried out. The decision will be taken on
coding rules and theme generation after consensus
among the investigators. Inductive as well as deductive
codes will be generated. Similar codes will be clubbed
together into themes. The themes will be described. The
findings will be reported by using Consolidated Criteria
for Reporting Qualitative Research [19].
Publication and dissemination of the results
The results of the trial will be presented in relevant na-
tional and/or international conferences and published in
a peer-reviewed journal. The results will also be dissemi-
nated through policy briefs and stakeholder meetings.
Print, electronic, and social media will be utilized to
share the results to non-specialist audiences.
Discussion
To the best of our knowledge, the m-Power Heart
Project is the first study to evaluate the effectiveness
of an NCC-led, mHealth-enabled intervention on
blood pressure control using a cluster randomized
trial design. Three previous studies in primary care
settings of India have demonstrated the effectiveness
of the mHealth intervention [7, 20, 21]. In the study
by Anchala et al. [20], the decision support system
was managed by the physicians and there were no
NCCs to support them. The SimCard trial [21] inter-
vention followed a simple 2 + 2 model – smoking ces-
sation and salt reduction plus anti-hypertensive
medication (calcium channel blocker 2.5/5 mg per
day) and aspirin (75 to 100 mg per day). In the
m-Power intervention study [7], the SBP reduced by
12.9 mmHg (95% CI: − 13.2 to − 12.7) in 3 months
and by 14.6 mmHg (95% CI: − 15.3 to − 13.8) in
18 months. In our study, we are testing the effective-
ness of EDSS through trained NCCs to decrease SBP
by 6.5 mmHg in the intervention arm compared to
the control. NCC together with EDSS is likely to ease
the burden of hypertension management on already
over-worked physicians in the public healthcare sys-
tem. Also, the intervention in the m-Power Heart
Project is more comprehensive than the SimCard trial
which includes hypertension management (based on
more than one class of anti-hypertensive and consid-
ering patient co-morbidities); screening, management,
and referral for CKD and SMS reminders.
Our study is timely and relevant. In June 2016, the
guidelines for the screening of hypertension, together
with other NCDs, was released by the Government
of India. The National Program for Prevention and
Control of Cancer, Diabetes, Cardiovascular Disease,
and Stroke (NPCDCS) recommends the setting up of
an “NCD Clinic” at the CHC [22]. Various activities,
like diagnosis and management, health promotion,
referral, data recording and reporting, are to be car-
ried out by personnel appointed, which includes two
nurses along with a medical officer. The m-Power
application and the structured training of nurses will
aid in better management of patients visiting the
CHC for care and subsequent reduction of blood
pressure resulting in improved health outcomes. We
hope that the evidence generated through the trial
will contribute to gaining acceptance and wider use
of the EDSS and task-shifting in India’s public
healthcare system.
Trial status
Recruitment is on-going.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOCX 49 kb)
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